Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial
{{output}}
Objective: This first-in-human, randomized, double-blind, placebo-controlled trial assessed the safety of NNC0114-0005, a human recombinant anti interleukin (IL)-21 monoclonal antibody, for the treatment of rheumatoid arthritis (... ...
